First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

No writing assistance was utilized in the production of this manuscript. Chikungunya virus (CHIKV) causes an acute febrile disease characterized by severe arthralgia in the small joints.

Zika transmission has been reported in more than 90 countries as the spread of the Aedes aegypti mosquito that carries the ...

If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.

The world’s first chikungunya vaccine, developed by French pharmaceutical firm Valneva SE, has been approved in the UK by the ...

While Zika has been reported in more than 90 countries, surprisingly little is known about what exactly drives Zika ...

Biological scientists from the National University of Singapore (NUS) have uncovered how the dengue virus uses its envelope ...

Biological scientists have uncovered how the dengue virus uses its envelope protein to capture human plasmin from a blood meal to enhance the permeability of the mosquito midgut for infection.